Bioseet
- Company typePrivate
- Founded2017
- HeadquartersMunich, Germany
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Bioseet firmographics
Firmographics- Name
- Bioseet
- Legal name
- BIOSEET GmbH
- Website
- https://bioseet.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Where Bioseet is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Bioseet business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Subscription: Subscription-based access to platform services with user-based licensing. Services are purchased as subscriptions subject to usage limitations. Fees are quoted in Euro and payable in advance. Subscriptions cannot be decreased during the relevant subscription term.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free access tier for asset listing |
| Subscription | Annual | Paid subscription for full platform access |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Bioseet product offering
Product offeringCore offering
Bioseet operates a digital SaaS partnering platform that enables pharmaceutical companies to search, list, and evaluate pipeline assets across innovative medicines, biosimilars, and generics. Companies can confidentially post assets or demands, evaluate opportunities with cross-functional teams using voting and commenting, and exchange with potential partners through secure anonymous chat rooms with mutual opt-in for identity disclosure.
Product overview
Bioseet is a unified digital partnering platform for the pharmaceutical industry that operates three marketplace verticals: the Innovative Medicine Marketplace, the Biosimilars Marketplace, and the Generics Marketplace. The core Bioseet Platform provides shared functionality including asset search, team-based evaluation, and secure anonymous exchange capabilities. Companies can list pipeline assets or post demands, evaluate opportunities with cross-functional teams using voting and commenting features, and communicate through secure chat rooms with mutual opt-in identity disclosure.
Differentiator
Problem solved
Functional benefit
Products and services
- Bioseet Platform A digital partnering platform that enables pharmaceutical companies to search for assets, evaluate partnering opportunities with their team, and exchange information with potential partners through secure chat rooms, with anonymous early-stage discussions and identity disclosure only upon mutual agreement.
- Innovative Medicine Marketplace A marketplace module for searching innovative medicines licensing opportunities and early-stage development assets, where asset holders can list assets confidentially and seekers can evaluate offerings based on molecule type, target, therapeutic area, development phase, pathway, technology, and IP status.
- Biosimilars Marketplace A marketplace module for searching biosimilars deals and evaluating biosimilar assets, where users can post available biosimilars assets or targeted demands without disclosing company name, and evaluate offerings with their team online.
- Generics Marketplace A marketplace module for searching generics deals and evaluating generics assets, supporting search by asset type, dossier availability, dosage form, primary packaging, and marketing authorization, where users can display assets or post target demands globally.
Companies that use Bioseet
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
Bioseet technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Bioseet partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights4 records
Bioseet competitors and assessment
Company assessmentBroad incumbents
- BioCentury: BioCentury is an established media and intelligence brand covering biotech business development, deal-making, and pipeline analysis. It serves the same pharma BD audience as Bioseet, primarily through editorial content and research.
- Acuris (Mergermarket): Acuris, owner of Mergermarket and DealReporter, provides M&A and deal intelligence across sectors including pharma and life sciences. It is a broad incumbent in deal data and a potential partner or competitor in the pharma BD workflow.
- Clarivate: Clarivate offers pharma intelligence, IP, and regulatory analytics (e.g., Cortellis, Derwent). It is a broad incumbent in the pharma data space and a potential competitive threat if it bundles partnering workflows into its existing subscriptions.
- Informa Pharma Intelligence (Citeline): Informa's Citeline franchise provides clinical trial, drug development, and commercial intelligence to pharma. It is a broad incumbent that overlaps with Bioseet on pharma BD intelligence and could expand into digital partnering as an adjacent product.
- PitchBook: PitchBook is a leading deal and private market data platform with growing coverage of biotech and pharma transactions. It is a broad incumbent on the data/analytics side of BD and is increasingly used by pharma licensing teams.
- GlobalData: GlobalData provides pharmaceutical market intelligence, deal tracking, and company analytics. It is a broad incumbent whose pharma deal coverage and company profiles overlap with the data and analytics layer of Bioseet's offering.
Emerging players
- Crunchbase: Crunchbase is a broad business deal and funding database with growing life sciences coverage. It is an emerging player in deal marketplaces and competes for the same buyer — the BD and corporate development user — that Bioseet serves in pharma.
Direct peers
- DealForma: DealForma operates a digital marketplace and analytics platform for pharmaceutical licensing and asset transactions. It is a direct competitor to Bioseet, serving the same pharma BD function with structured deal data and partner-matching tools.
- EBD Group (PartneringONE): EBD Group runs the PartneringONE platform that powers one-to-one meetings at BIO Convention, BIO-Europe, and other major pharma partnering events. It is a direct competitor to Bioseet's digital partnering offering, focused on facilitating BD meetings between pharma and biotech.
- PharmaVentures: PharmaVentures provides pharma transaction advisory, licensing deal data (PharmaDeals), and partnering support services. It is comparable to Bioseet in serving pharma BD and licensing workflows, though it is more consultancy-led than platform-led.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Bioseet social profiles
Digital presenceBioseet financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioseet leadership team
Management profileNumber of profiles
Profiles3 records
Bioseet funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioseet M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioseet
What does Bioseet do?
Bioseet operates a digital SaaS partnering platform that enables pharmaceutical companies to search, list, and evaluate pipeline assets across innovative medicines, biosimilars, and generics. Companies can confidentially post assets or demands, evaluate opportunities with cross-functional teams using voting and commenting, and exchange with potential partners through secure anonymous chat rooms with mutual opt-in for identity disclosure.
Is Bioseet a public or private company?
Bioseet is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Bioseet founded?
Bioseet was founded in 2017. It employs 1 to 10 people.
Where is Bioseet based?
Bioseet is headquartered in Munich, Germany, in the Europe region.
How does Bioseet make money?
One revenue line is on record: platform Subscription.
Who are Bioseet's main competitors?
Broad incumbents on record are BioCentury, Acuris (Mergermarket), Clarivate, Informa Pharma Intelligence (Citeline), PitchBook and GlobalData. Crunchbase is listed as an emerging player. Direct peers are DealForma, EBD Group (PartneringONE) and PharmaVentures.
Does Bioseet have an API?
No public API is recorded for Bioseet.